Tibotec Pharmaceuticals Submits New Drug Application for Investigational Once-Daily HIV Treatment TMC278 to U.S. Food and Drug Administration
TITUSVILLE, N.J., July 26 /PRNewswire/ -- Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside...
Short URL: http://drugrehab.in/?p=65874
Posted by admin
on Jul 26 2010. Filed under drug applications.
You can follow any responses to this entry through the RSS 2.0.
Both comments and pings are currently closed.
